Back to Search
Start Over
Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
- Source :
-
Journal of neuroimmunology [J Neuroimmunol] 2016 Sep 15; Vol. 298, pp. 24-31. Date of Electronic Publication: 2016 Jun 24. - Publication Year :
- 2016
-
Abstract
- Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.<br /> (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Collagen Type I urine
Disability Evaluation
Female
Humans
Male
Middle Aged
Multiple Sclerosis drug therapy
Multiple Sclerosis urine
Peptide Fragments metabolism
Peptides urine
Procollagen metabolism
Tartrate-Resistant Acid Phosphatase metabolism
Bone Resorption drug therapy
Bone Resorption etiology
Fingolimod Hydrochloride therapeutic use
Immunosuppressive Agents therapeutic use
Multiple Sclerosis complications
Sex Characteristics
Subjects
Details
- Language :
- English
- ISSN :
- 1872-8421
- Volume :
- 298
- Database :
- MEDLINE
- Journal :
- Journal of neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 27609272
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2016.06.007